Study of a drug combination for breast cancer that spread to the brain
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This trial tests whether a combination of three drugs (SHR-A1811, pyrotinib, and bevacizumab) can help people with advanced breast cancer that has spread to the brain. It aims to shrink brain tumors and stop them from growing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have advanced breast cancer with at least one untreated brain tumor seen on an MRI
- You are generally well enough to be up and about for at least half the day (ECOG score 0-2)
- Your major organs (like kidneys and liver) are working well
- You have not had whole-brain radiation, chemotherapy, or major surgery in the last 2 weeks
- You do not have certain severe lung diseases or bleeding problems
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug (SHR-A1811) combined with radiation therapy for breast cancer that has spread to the brain. The goal is to see if this combination can help control the brain tumors and possibly improve outcomes.
This trial tests whether SPH4336, added to standard hormone (endocrine) therapy, can improve outcomes for people with breast cancer that has spread to the brain. It also looks closely at safety and side effects.
This trial tests a new drug combined with other anti-cancer drugs for advanced breast cancer. The goal is to see if the combination can shrink tumors and help people live longer, and if it is safe.
This trial is testing whether giving radiation therapy along with a combination of chemotherapy (cisplatin or carboplatin), an immunotherapy drug called adebrelimab, and a drug called bevacizumab can better treat triple-negative breast cancer that has spread to the brain. The goal is to see if this combination can shrink or control the brain tumors and improve outcomes.
This trial tests a combination of two drugs (Sac-TMT and bevacizumab) to treat triple-negative breast cancer that has spread to the brain. Triple-negative means the cancer cells lack three common markers, making it harder to treat with standard therapies.
This Phase 2 study tests SHR-A1811 in people with HER2-positive (or HER2-low) advanced breast cancer that has spread to the brain. It aims to shrink brain tumors and control the cancer in the brain, especially when there was no need for urgent local treatment like radiation or surgery.
Hear when a new Breast Cancer Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.